BRUSSELS, May 15, 2025 (GLOBE NEWSWIRE) -- Anbio Biotechnology, a global leader in in-vitro diagnostic (IVD) technologies, is pleased to announce its participation in three major international exhibitions this May: EuroMedLab 2025 in Brussels, AVA Conference 2025 in Sydney, and the 47th ACMTT 2025 in Bangkok. These events reflect Anbio's strategic commitment to expanding its global footprint across human and animal healthcare, building new partnerships, and sharing its vision for accessible, high-performance diagnostics. As healthcare systems around the world seek faster, more accurate, and decentralized testing solutions, Anbio is well-positioned to meet this demand through a diversified

Frankfurt am Main, Germany, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Anbio Biotechnology (the "Company" or "Anbio"), a global diagnostic company dedicated to the advancement of medical technology and the provision of in vitro diagnostics products, today announced the closing of its initial public offering (the "Offering") of 1,600,000 Class A ordinary shares (the "Class A Ordinary Shares") at a public offering price of US$5.00 per Class A Ordinary Share. The Class A Ordinary Shares began trading on the Nasdaq Global Market on February 19, 2025 under the ticker symbol "NNNN." The Company received aggregate gross proceeds of US$8 million from the Offering, before deducting underwriting discounts a

20-F - Anbio Biotechnology (0001982708) (Filer)

6-K - Anbio Biotechnology (0001982708) (Filer)